Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 2/20 | 0.38 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239180 | 0.84 | TAAR1 (0.42) | TOP2ATOP2BKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL1935594 | 0.83 | TAAR1 (0.41) | TOP2ATOP2BKDM4EMAPT | |
| SCHEMBL14085132 | 0.82 | TOP2A (0.44) | TOP2ATOP2BF10 | |
| SCHEMBL4035735 | 0.80 | NCF1 (0.41) | NCF1ADRB2TOP2ATOP2BLOXL2 | |
| SCHEMBL4028424 | 0.77 | PTGS2 (0.38) | F10 | |
| SCHEMBL18297326 | 0.77 | HTT (0.41) | CYP3A4MAPT | |
| Water SCHEMBL9451273 | 0.76 | PTAFR (0.43) | TOP2ATOP2BF10 | |
| Water SCHEMBL9451270 | 0.76 | PTAFR (0.43) | TOP2ATOP2BF10 | |
| SCHEMBL8286902 | 0.75 | PTAFR (0.46) | TOP2ATOP2BF10 | |
| SCHEMBL5502730 | 0.74 | TOP2A (0.36) | TOP2ATOP2BF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521744-B1 | ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS | FOURNIER LAB SA (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | NCF1 941/4885ADRB2 2178/4885TOP2A 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.